Peripheral Arterial Disease: A Growing Global Epidemic
Peripheral Arterial Disease (PAD) represents a significant and escalating global health challenge, characterized by the narrowing of peripheral arteries, most commonly in the legs. This condition restricts blood flow, leading to pain, impaired mobility, and, in severe cases, limb amputation. Recent projections underscore the alarming trajectory of PAD, positioning it as a rapidly expanding epidemic with profound implications for public health systems worldwide [1].
According to a comprehensive population-based study, the global burden of PAD is anticipated to surge dramatically. The number of PAD cases worldwide is projected to increase by an astounding 220% between 2021 and 2050, potentially affecting 360 million individuals. This rise is not merely a reflection of population growth but also an increase in age-standardized prevalence rates, which are expected to climb by 164% over the same period. Concurrently, age-standardized mortality is forecasted to double, and disability-adjusted life years (DALYs) are projected to increase by 68% [1]. These figures highlight the escalating morbidity and mortality associated with PAD, particularly among older adults, and disproportionately impacting low- and middle-income countries (LMICs), where over half of future cases are expected to occur [1].
The primary drivers behind this growing epidemic are multifaceted, with modifiable risk factors playing a pivotal role. Metabolic diseases, especially diabetes, are identified as the most significant contributors to the rising PAD burden. Diabetes alone is projected to affect 1.31 billion people globally by 2050, substantially increasing PAD prevalence and severity [1, 2]. Other critical modifiable risk factors include smoking, obesity, hypertension, and hyperlipidemia, which collectively account for approximately 70% of PAD cases [2]. Non-traditional risk factors, such as chronic kidney disease (CKD), also contribute significantly, with CKD patients facing a heightened risk of limb amputations and cardiovascular events [1]. While anti-smoking initiatives have shown some success, their benefits are increasingly offset by the escalating prevalence of metabolic risks and an aging global population [1].
Despite the growing prevalence, PAD remains under-recognized and undertreated. Limited public and professional awareness, coupled with atypical symptom presentation in many patients (only 10% to 30% experience classic intermittent claudication), often leads to delayed diagnosis [1, 3]. Diagnostic tools like the ankle-brachial index (ABI) are crucial for early detection, yet access to such non-invasive tests and subsequent guideline-recommended therapies remains suboptimal, particularly in resource-limited settings [1, 4]. Supervised exercise therapy, a first-line treatment, has demonstrated efficacy comparable to endovascular interventions but faces implementation challenges due to inadequate healthcare infrastructure [1].
Addressing this burgeoning epidemic necessitates a concerted global effort. Proactive management of metabolic risk factors, particularly diabetes, could significantly reduce the projected PAD burden, with estimates suggesting a 36% reduction in age-standardized prevalence, a 17% reduction in mortality, and a 10% reduction in DALYs by 2050 through effective interventions [1]. This underscores the potential for preventing over 30% of PAD cases through targeted risk factor management. Strategies must focus on increasing public and healthcare provider awareness, improving access to diagnostic services, and ensuring equitable distribution of PAD management resources globally. Government health agencies must lead in strengthening PAD-related policies and expanding treatment options, especially in regions with limited healthcare infrastructure [1].
In conclusion, Peripheral Arterial Disease is rapidly emerging as a major global health crisis, driven by an aging population and the increasing prevalence of metabolic risk factors. The projected rise in cases, mortality, and disability demands urgent and comprehensive public health interventions. By prioritizing awareness, early diagnosis, and aggressive management of modifiable risk factors, the trajectory of this growing epidemic can be altered, leading to improved health outcomes and reduced healthcare burdens worldwide.
References
[1] Deng, L., Du, C., Liu, L., Wang, Y., Gu, H., Armstrong, D. G., ... & Deng, W. (2025). Forecasting the Global Burden of Peripheral Artery Disease from 2021 to 2050: A Population-Based Study. *Research (Wash D C)*, *8*, 0702. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12209533/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12209533/) [2] GBD 2019 Peripheral Artery Disease Collaborators. (2023). Global burden of peripheral artery disease and its risk factors, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. *Lancet Glob Health*, *11*(10), e1553–e1565. [3] Polonsky, T. S., & McDermott, M. M. (2021). Lower extremity peripheral artery disease without chronic limb-threatening ischemia: A review. *JAMA*, *325*(21), 2188–2198. [4] Bauersachs, R., Zeymer, U., Brière, J. B., Marre, C., Bowrin, K., & Huelsebeck, M. (2019). Burden of coronary artery disease and peripheral artery disease: A literature review. *Cardiovasc Ther*, *2019*, 8295054.